Gastroenterology
Volume 133, Issue 2 , Pages 412-422 , August 2007

Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based Cohort

  • Kathrine Frey Frøslie

      Affiliations

    • Section of Biostatistics, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway
    • ,
  • Jørgen Jahnsen

      Affiliations

    • Medical Department, Aker University Hospital, Oslo, Norway
    • ,
  • Bjørn A. Moum

      Affiliations

    • Medical Department, Aker University Hospital, Oslo, Norway
    • ,
  • Morten H. Vatn

      Affiliations

    • Medical Department, Rikshospitalet-Radiumhospitalet Medical Center and Epi-Gen Ahus, Faculty of Medicine, University of Oslo, Norway
    • Corresponding Author InformationAddress requests for reprints to: Morten H. Vatn, MD, University of Oslo, Faculty Division Ahus, PO Box 75, 1474 Nordbyhagen, Norway. fax: (47) 23 07 36 43.
    • ,
  • IBSEN Group

Received 15 June 2006 ,Accepted 19 August 2007.

References 

  1. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel CF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet. 2002;359:1541–1549
  2. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Comparison of scheduled and episodic treatment strategies of Infliximab in Crohn’s disease. Gastroenterology. 2004;126:402–413
  3. Lemann M, Mary J-Y, Colombel JF, Duclos B, Soule JC, Lerebours E, et al. (GETAID) A randomised, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine. Gastroenterology. 2005;128:1812–1818
  4. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulising Crohn’s disease. Gastroenterology. 2005;128:862–869
  5. Moum BA, Vatn MH, Ekbom A, Fausa O, Aadland E, Lygren I, et al. Incidence of inflammatory bowel disease in southeastern Norway: evaluation of methods 1 year after registration. Digestion. 1995;56:377–381
  6. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989;24(Suppl 170):2–6
  7. Altman DG. Practical statistics for medical research. London, UK: Chapman & Hall; 1991;
  8. Hosmer DW, Lemeshow S. In: Applied logistic regression. 2nd edition. New York: Wiley; 2000;
  9. Fox J. Cox proportional-hazard regression for survival data. Appendix to An R and S-PLUS companion to applied regression. 2002;February. Available at: http://cran.r-project.org/doc/contrib/Fox-Companion/appendix-cox-regression.pdf. Accessed February/March 2006.
  10. de Lange T, Larsen S, Aabakken L. Inter-observer agreement in the assessment of endoscopic findings in ulcerative colitis. BMC Gastroenterol. 2004;4:9
  11. Hanauer SB, Sandborn WJ, Kornbluth A, Katz , Safdi M, Woogen S, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The Ascend II trial. Am J Gastroenterol. 2005;100:2478–2485
  12. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476
  13. D’Haens G. Mucosal healing in pediatric Crohn’s disease: the goal of medical treatment. Inflamm Bowel Dis. 2004;10:479–480

 Supported partially by CENTOCOR INC. for the IBSEN study.

 There is no conflict of interest for any of the authors.

PII: S0016-5085(07)01102-X

doi: 10.1053/j.gastro.2007.05.051

Gastroenterology
Volume 133, Issue 2 , Pages 412-422 , August 2007

Article Tools

* Image Usage & Resolution